Novartis, Argo Biopharma Expand Strategic Alliance with USD 5.2 Billion Cardiovascular Drugs Deal

Novartis, Argo Biopharma expand strategic alliance with USD 5.2 billion Cardiovascular drugs deal

Shanghai: Argo Biopharmaceutical Co., Ltd., a clinical-stage biotechnology company focused on developing next-generation siRNA therapeutics, has announced that it has entered into an additional...

Novartis pens $5.2bn cardiovascular partnership with Argo

Novartis is paying $160m upfront to activate an expanded R&D alliance with China's Argo Biopharma covering multiple cardiovascular disease drugs.

Novartis licenses RNA drugs in deal with China-based Argo

The alliance, which could be worth more than $5 billion, is one of a handful of deals Novartis has struck with China-based biotechs in recent years.

Novartis adds again to siRNA pipeline with second deal in a day - Pharmaceutical Technology

Novartis has returned to Argo for rights to multiple of the biotech’s clinical stage assets.

Novartis returns to Shanghai biotech Argo for another multibillion-dollar siRNA deal

For the second day in a row, Novartis is promising billions of dollars in biobucks to a company developing siRNA medicines. This time, Novartis is returning to a familiar face in Shanghai. The Swiss drugmaker ...

Massive $5.2B Biotech Deal: Argo's Novel Heart Disease Drugs Draw Novartis Partnership with $160M Upfront

Argo Biopharma partners with Novartis in cardiovascular drug development, including Phase 2 ANGPTL3 and siRNA candidates. Deal includes $160M upfront, potential $5.2B in milestones, and P&L sharing options.